New genome research reports that the genetic makeup can depict liability to prostate cancer. Prostate cancer is the second most frequent cancer after skin cancer. Most men of a high age will have markers of prostate cancer when diagnosed. There will be many small lesions but some can result to turn out very intense and dangerous markers. It is still a hurdle to find the difference between ones, which might result perilous and the one that will not. This makes treatment inescapable and compulsory for either of the cases.
Research made published from the Proceeding of the National Academy of Science, proclaims a new “improved method to diagnose”. A particular genetic variant has been identified that distinguishes the two markers of prostate cancer. The slow from the aggressive variant, which make it easier to treat prostate cancer.
These findings will hastily proliferate in the market. It will help to reduce treatments and eliminate extensive-diagnosis that are usually unnecessary for this common cancer. In America above 27, 000 men dies each year from prostate cancer. According to Karim Kader, an urologist at Wake Forest University School of Medicine in Winston-Salem, N.C, and study collaborator, avoiding over-treatment can be a great step forward.
The research was conducted on a sample consisting of approximately 17, 000 men from Sweden and U.S having prostate cancer. The genetic variant rs4054823 (Marker for the aggressive type) is highly differentiated for aggressive prostate cancer in respect to the slower variant of the disease. According to the research, finding the variant does not imply that solutions to treat prostate cancer will be made available soon. It only gives greater hopes for potential treatment.
Jianfeng Xu, a professor of epidemiology and cancer biology at Wake Forest and lead study author, said, “A single variant with a moderate effect such as this is unlikely to be sufficient on its own at predicting risk,”. Moreover, according to him it shows that aggressive disease can be delved from the genome. “We believe it has the potential to one day be used in combination with other clinical variables and genetic markers to predict which men have aggressive prostate cancer.”
There have been obsessive debated on cancer diagnosis and screening after “March 2009 report that said that prostate-specific antigen (PSA) blood analysis (test)” might unfortunately not be as life saving as foreseen. This was reported by New England Journal of medicine; conducting PSA, screening does not have a substantial effect on the number of people who will die from the cancer.
According to the research, genetic testing might both help medical practitioners to better screen low from high-risk patients of the cancer. In addition, in the future these genetic tests would make it possible to identify the cancer before it emerge or at an early stage where it is treatable.
Source: Scientific America
Fri, Jan 22, 2010
Bioscience, Health And Aging